Press Releases
Walnut Creek – Today, Congressman Mark DeSaulnier (CA-11) announced legislation to prevent incidents in which federal law enforcement officers’ service weapons are lost or stolen. Earlier this week, a loaded Glock 27 was stolen out of an FBI agent’s car in San Francisco. This is just one example of a concerning trend involving a stolen weapon from federal law enforcement in the San Francisco area.
Washington, D.C. – Today, Representatives Mark DeSaulnier (D-CA) and Earl L. “Buddy” Carter (R-GA) introduced legislation to better inform patients, doctors, and pharmacists on prescription drug dispensing. The Empowering Pharmacists in the Fight Against Opioid Abuse Act (H.R.
Washington, D.C. – Congressman Mark DeSaulnier (CA-11) made the following statement on the National Defense Authorization Act (NDAA) for FY2017 which passed the U.S House of Representatives by a vote of 277 to 147.
“Ensuring the safety and security of our country and our troops should be Congress’s top priority. During a time of such international volatility, providing our military with the resources they need to fight traditional and nontraditional threats is imperative.
Washington, DC – Today, the US House of Representatives passed a package of bipartisan bills aimed at addressing the opioid abuse crisis including the Comprehensive Opioid Abuse Reduction Act (H.R. 5046). This bill would authorize $103 million in grants to states for programs aimed at providing substance abuse treatment.
Washington, DC – Today, Representative Mark DeSaulnier (CA-11) unveiled his new Congressional website, which can be accessed at www.desaulnier.house.gov. The new site features a clean, modern design that provides constituents with the latest news impacting their community, information about constituent services, and opportunities to connect with the Congressman.
“Last summer, I was diagnosed with the most common leukemia in the world, a cancer named Chronic lymphocytic leukemia (CLL). I recently completed aggressive chemotherapy. I feel fortunate that I had a positive response to this treatment, and that neither CLL nor the treatment impacted my professional work.